% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Schuepbach:860977,
author = {Schuepbach, W. M. Michael and Tonder, Lisa and Schnitzler,
Alfons and Krack, Paul and Rau, Joern and Hartmann, Andreas
and Hälbig, Thomas and Pineau, Fanny and Falk, Andrea and
Paschen, Laura and Paschen, Stephen and Volkmann, Jens and
Dafsari, Haidar S. and Barbe, Michael and Fink, Gereon R.
and Kühn, Andrea and Kupsch, Andreas and Schneider, Gerd-H.
and Seigneuret, Eric and Fraix, Valerie and Kistner, Andrea
and Chaynes, P. Patrick and Ory-Magne, Fabienne and
Brefel-Courbon, Christine and Vesper, Jan and Wojtecki, Lars
and Derrey, Stéphane and Maltête, David and Damier,
Philippe and Derkinderen, Pascal and Sixel-Döring,
Friederike and Trenkwalder, Claudia and Gharabaghi, Alireza
and Wächter, Tobias and Weiss, Daniel and Pinsker, Marcus
O. and Regis, Jean-Marie and Witjas, Tatiana and Thobois,
Stephane and Mertens, Patrick and Knudsen, Karina and
Schade-Brittinger, Carmen and Houeto, Jean-Luc and Agid,
Yves and Vidailhet, Marie and Timmermann, Lars and Deuschl,
Günther},
title = {{Q}uality of life predicts outcome of deep brain
stimulation in early {P}arkinson disease},
journal = {Neurology},
volume = {92},
number = {10},
issn = {1526-632X},
address = {[S.l.]},
publisher = {Ovid},
reportid = {FZJ-2019-01610},
pages = {e1109},
year = {2019},
abstract = {Objective To investigate predictors for improvement of
disease-specific quality of life (QOL) after deep brain
stimulation (DBS) of the subthalamic nucleus (STN) for
Parkinson disease (PD) with early motor
complications.Methods We performed a secondary analysis of
data from the previously published EARLYSTIM study, a
prospective randomized trial comparing STN-DBS (n = 124) to
best medical treatment (n = 127) after 2 years follow-up
with disease-specific QOL (39-item Parkinson's Disease
Questionnaire summary index [PDQ-39-SI]) as the primary
endpoint. Linear regression analyses of the baseline
characteristics age, disease duration, duration of motor
complications, and disease severity measured at baseline
with the Unified Parkinson’s Disease Rating Scale (UPDRS)
(UPDRS-III “off” and “on” medications, UPDRS-IV)
were conducted to determine predictors of change in
PDQ-39-SI.Results PDQ-39-SI at baseline was correlated to
the change in PDQ-39-SI after 24 months in both treatment
groups (p < 0.05). The higher the baseline score (worse QOL)
the larger the improvement in QOL after 24 months. No
correlation was found for any of the other baseline
characteristics analyzed in either treatment
group.Conclusion Impaired QOL as subjectively evaluated by
the patient is the most important predictor of benefit in
patients with PD and early motor complications, fulfilling
objective gold standard inclusion criteria for STN-DBS. Our
results prompt systematically including evaluation of
disease-specific QOL when selecting patients with PD for
STN-DBS.},
cin = {INM-3},
ddc = {610},
cid = {I:(DE-Juel1)INM-3-20090406},
pnm = {572 - (Dys-)function and Plasticity (POF3-572)},
pid = {G:(DE-HGF)POF3-572},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:30737338},
UT = {WOS:000463252900018},
doi = {10.1212/WNL.0000000000007037},
url = {https://juser.fz-juelich.de/record/860977},
}